
Question Regarding 483 Responses - Provenge, February 23, 2010


 
(System Info - 126945 TULL LORI 04/25/2010 13:03:10 TULL)

From: Wang, Gang
 Sent: Wednesday, February 03, 2010 1:59 AM
 To: 'Smith, Liz'; Finn, Thomas
 Cc: Tull, Lori; Syin, Chiang
 Subject: RE: Question regarding 483 responses

Hi Liz, please see my responses to your questions. Let me know if there?s 
anything unclear. Thanks.

Gang

--------------------------------------------------------------------------------

From: Smith, Liz [mailto:lsmith@Dendreon.com]
 Sent: Tuesday, February 02, 2010 6:31 PM
 To: Finn, Thomas; Wang, Gang
 Cc: Tull, Lori
 Subject: Question regarding 483 responses

Dear Tom and Gang,

We are planning to submit the responses to the 483s next week. Can you please 
advise us on the following?

1) Where (name and address) should the responses be submitted and how many 
copies are desired? [Wang, Gang] it should be send as an amendment to BLA 
indicating it is inspection related. E-submission is preferred. Please copy all 
inspectors.

2) Should we also plan on submitting the responses as an amendment to the BLA? 
[Wang, Gang] yes, see above.

3) Do you need the production history summary (i.e., lots produced during 
inspection, including in process, final product test results, EM) with the 483 
responses, or can we provide once final sterility results are reviewed and 
investigation complete? This would all be available shortly after the 483 
responses are submitted. [Wang, Gang] you could submit the information as a 
separate amendment to BLA indicating it is inspection related. Please include 
the all the information you mentioned plus all the final testing results. 
Include all the deviations occurred if there?s any. The timing of aphresis 
receiving at Dendreon and product receiving at the infusion sites should also be 
included. Please also include the investigational report for the incident 
happened to one of the lots manufacturing during the inspection.

We also plan to submit a CMC and Facility Update amendment as discussed with Tom 
under separate cover in the next 7-10 days. [Wang, Gang] I agree it should be 
submitted as an amendment to BLA.

Thanks for your help,

Liz

 

********************************************
 Elizabeth C. Smith
 Vice President of Regulatory Affairs
 Dendreon Corporation
 3005 First Ave
 Seattle, WA 98121
 t: 206.829.1556/ f: 206.219.1004/ m. 206.719.4366
esmith@dendreon.com

*******************************************

--------------------------------------------------------------------------------

This email message including any attachments is for the sole use of the intended 
recipient(s) and may contain confidential and privileged information. Any 
unauthorized review, use, disclosure or distribution is prohibited. If you are 
not the intended recipient, please contact the sender by reply email and destroy 
all copies of the original message. If you are the intended recipient, please be 
advised that the content of this message is subject to access, review and 
disclosure by the sender's Email System Administrator.

 
